294 related articles for article (PubMed ID: 34392725)
1. Risk of Developing Melanoma With Systemic Agents Used to Treat Psoriasis: A Review of the Literature.
Semaka A; Salopek TG
J Cutan Med Surg; 2022; 26(1):87-92. PubMed ID: 34392725
[TBL] [Abstract][Full Text] [Related]
2. Melanocytic nevus count and dermoscopic features do not differ in psoriatic patients undergoing biological agent versus conventional drug therapy.
Pirmit S; Onsun N; Su O; Ozkaya DB
G Ital Dermatol Venereol; 2017 Apr; 152(2):126-131. PubMed ID: 28166613
[TBL] [Abstract][Full Text] [Related]
3. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
[TBL] [Abstract][Full Text] [Related]
4. Adverse Reactions to Biologics in Psoriasis.
Lockwood SJ; Prens LM; Kimball AB
Curr Probl Dermatol; 2018; 53():1-14. PubMed ID: 29131033
[TBL] [Abstract][Full Text] [Related]
5. Risk of cancer in patients with psoriasis on biological therapies: a systematic review.
Peleva E; Exton LS; Kelley K; Kleyn CE; Mason KJ; Smith CH
Br J Dermatol; 2018 Jan; 178(1):103-113. PubMed ID: 28722163
[TBL] [Abstract][Full Text] [Related]
6. Adverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based Analysis.
Wu JJ; Armstrong A; Singh R; Cloutier M; Gauthier-Loiselle M; Gagnon-Sanschagrin P; Arikan D; Fleischer A; Guérin A; Ganguli A
J Drugs Dermatol; 2018 Nov; 17(11):1211-1218. PubMed ID: 30500143
[TBL] [Abstract][Full Text] [Related]
7. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest.
Reich K; Mrowietz U; Radtke MA; Thaci D; Rustenbach SJ; Spehr C; Augustin M
Arch Dermatol Res; 2015 Dec; 307(10):875-83. PubMed ID: 26358263
[TBL] [Abstract][Full Text] [Related]
8. [New systemic treatments for psoriasis: etanercept, infliximab, adalimumab, efalizumab and alefacept].
Bos WE; Thio HB; Neumann HA; van der Fits L; Prens EP
Ned Tijdschr Geneeskd; 2006 May; 150(19):1065-70. PubMed ID: 16733982
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of systemic therapies for moderate to severe psoriasis.
Sizto S; Bansback N; Feldman SR; Willian MK; Anis AH
Br J Dermatol; 2009 Jun; 160(6):1264-72. PubMed ID: 19120346
[TBL] [Abstract][Full Text] [Related]
10. [Long term treatment of psoriasis with TNF-alpha antagonists. Occurrence of malignant melanoma].
Kowalzick L; Eickenscheidt L; Komar M; Schaarschmidt E
Hautarzt; 2009 Aug; 60(8):655-7. PubMed ID: 19280165
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical setting.
Takeshita J; Wang S; Shin DB; Callis Duffin K; Krueger GG; Kalb RE; Weisman JD; Sperber BR; Stierstorfer MB; Brod BA; Schleicher SM; Robertson AD; Linn KA; Shinohara RT; Troxel AB; Van Voorhees AS; Gelfand JM
J Am Acad Dermatol; 2014 Dec; 71(6):1167-75. PubMed ID: 25260564
[TBL] [Abstract][Full Text] [Related]
12. Elderly psoriatic patients under biological therapies: an Italian experience.
Ricceri F; Bardazzi F; Chiricozzi A; Dapavo P; Ferrara F; Mugheddu C; Romanelli M; Rongioletti F; Prignano F
J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):143-146. PubMed ID: 29906311
[TBL] [Abstract][Full Text] [Related]
13. To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis.
Ahn CS; Dothard EH; Garner ML; Feldman SR; Huang WW
J Am Acad Dermatol; 2015 Sep; 73(3):420-8.e1. PubMed ID: 26184440
[TBL] [Abstract][Full Text] [Related]
14. Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumab.
Bagel J; Tyring S; Rice KC; Collier DH; Kricorian G; Chung J; Iles J; Stolshek BS; Kaliyaperumal A; Papp KA
Br J Dermatol; 2017 Aug; 177(2):411-418. PubMed ID: 28196270
[TBL] [Abstract][Full Text] [Related]
15. Treatments for psoriasis and the risk of malignancy.
Patel RV; Clark LN; Lebwohl M; Weinberg JM
J Am Acad Dermatol; 2009 Jun; 60(6):1001-17. PubMed ID: 19344980
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials].
Zhang Z; Schmitt J; Wozel G; Kirch W
Med Klin (Munich); 2009 Feb; 104(2):125-36. PubMed ID: 19242664
[TBL] [Abstract][Full Text] [Related]
17. Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis.
Phan C; Beauchet A; Burztejn AC; Severino-Freire M; Barbarot S; Girard C; Lasek A; Reguiai Z; Hadj-Rabia S; Abasq C; Brenaut E; Droitcourt C; Perrussel M; Mallet S; Phan A; Lacour JP; Khemis A; Bourrat E; Chaby G; Deborde R; Plantin P; Maruani A; Piram M; Maccari F; Fougerousse AC; Kupfer-Bessaguet I; Balguérie X; Barthelemy H; Martin L; Quiles-Tsimaratos N; Mery-Brossard L; Pallure V; Lons-Danic D; Bouilly-Auvray D; Beylot-Barry M; Puzenat E; Aubin F; Mahé E; ;
J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):1984-1992. PubMed ID: 30883928
[TBL] [Abstract][Full Text] [Related]
18. Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-analysis.
Esse S; Mason KJ; Green AC; Warren RB
JAMA Dermatol; 2020 Jul; 156(7):787-794. PubMed ID: 32432649
[TBL] [Abstract][Full Text] [Related]
19. An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: a review of the efficacy and safety of biologics and prebiologic options.
Leon A; Nguyen A; Letsinger J; Koo J
Expert Opin Pharmacother; 2007 Apr; 8(5):617-32. PubMed ID: 17376017
[TBL] [Abstract][Full Text] [Related]
20. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
Weinberg JM
Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
